an old drug
a controversial treatment
successful across a range of diseases linked
by immune system dysfunction
YOU won't hear of it, and YOU won't be offered it
On October 19th, patients, physicians and researchers alike will convene at the National Institutes of Health in Bethesda, MD, for the Fifth Annual Conference on Low Dose Naltrexone.
October 19th will also kick off the First International LDN Awareness Week – a concerted push to get the word out through the media, about thousands of patients with autoimmune diseases who are benefitting from the off-label use of one inexpensive generic drug protocol, low dose naltrexone (commonly referred to as LDN).
It is estimated that thousands of patients worldwide are now enjoying improved health due to LDN. Most learn about it through a combination of word of mouth, success stories, internet research, online forums, and an ever-growing number of doctors who are prescribing it for their patients with autoimmune diseases.
The LDN protocol employs approximately 1/10 the dose of naltrexone, a drug that was approved in 1984 by the FDA to treat alcoholism and drug addiction. Today, thanks to the work of patient advocates, dedicated physicians and researchers, thousands of patients are taking LDN to successfully halt the progression of diseases that are compromised by an impaired immune system, such as Multiple Sclerosis, HIV, Rheumatoid Arthritis, Crohn’s Disease, Lupus and Fibromyalgia.
Low Dose Naltrexone (LDN) is literally changing their lives.
“Before I started taking LDN in 2003, I was an invalid,” says Linda Elsegood, one of the founders of the LDN Research Trust, a non-profit charity in England, which was formed in 2004 to raise both awareness of and research for LDN. “I had just about every symptom of Multiple Sclerosis that a person